The Bcl2 family of proteins plays a critical role in regulating MOMP, and the clinical inhibitor of Bcl2, venetoclax, has demonstrated marked effectiveness in treating chronic lymphocytic leukaemia (Lew & Seymour, 2022). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.